What is Belimumab?
Belimumab is a medication used to treat systemic lupus erythematosus (SLE), a chronic autoimmune disease that can affect various parts of the body. It is a monoclonal antibody that works by inhibiting the activity of a protein called B lymphocyte stimulator (BLyS), which is involved in the development and activation of B cells, a type of immune cell.
[1] (https://www.drugs.com/pro/benlysta.html)
How does Belimumab work?
Belimumab specifically targets and binds to BLyS, preventing it from interacting with B cells and reducing their activity. This leads to a decrease in the production of antibodies, which are proteins produced by B cells that can attack healthy tissues and contribute to the inflammation and damage seen in SLE.
[1]
What is a biosimilar of Belimumab?
A biosimilar of Belimumab is a medicine that is highly similar to the original drug but is not an exact copy. Biosimilars are developed after the patent for the original drug has expired and can be produced by different manufacturers.
According to [2] (DrugPatentWatch.com), a biosimilar of Belimumab, also known as Benlysta, is currently in development.
When will the biosimilar be available?
The exact timing for the release of the Belimumab biosimilar is not yet known. However, as the patent for Benlysta expires, more biosimilars are likely to be developed and approved for use.
Why is a biosimilar needed?
Biosimilars offer a more affordable alternative to name-brand biologics, such as Belimumab. They can reduce healthcare costs and make more treatments available to patients who may not have access to them otherwise.
What are the possible side effects of Belimumab and biosimilars?
The side effects of Belimumab and its biosimilars include allergic reactions, headaches, fatigue, muscle pain, and respiratory infections. More serious side effects, such as liver damage and a severe allergic reaction called anaphylaxis, have also been reported.
[3] (National Institutes of Health)
Regulatory approval and market access
Regulatory approval for biosimilars depends on various countries' regulatory requirements. Generally, biosimilars must demonstrate comparable safety, efficacy, and quality to the original biologic before approval.
Additional resources
For more information about Belimumab and biosimilars, consult sources such as the National Lupus Foundation of America, the Lupus Research Alliance, or DrugPatentWatch.com.
References:
[1] Drugs.com. (n.d.). Benlysta (belimumab): Side effects, uses, and dosage. Retrieved from https://www.drugs.com/pro/benlysta.html
[2] DrugPatentWatch.com. (n.d.). Benlysta (belimumab): Patent expiration and biosimilars. Retrieved from https://www.drugpatentwatch.com/brand/benlysta
[3] National Institutes of Health. (n.d.). Systemic lupus erythematosus (SLE). Retrieved from https://ghr.nlm.nih.gov/condition/systemic-lupus-erythematosus